These materials contain important information about the risks associated with valproate (Epilim▼) in female children and women of childbearing potential and pregnant women. They were developed in agreement with the Health Products Regulatory Authority (HPRA) and are available to healthcare professionals and patients.
▼This medicinal product is subject to additional monitoring.
Suspected side effects should be reported to HPRA Pharmacovigilance at www.hpra.ie (information about reporting side effects).
You can also report side effects directly to Sanofi on IEPharmacovigilance@sanofi.com or + 353 1 403 5600.
You can contact our medical information team for further information at IE-Medicalinformation@sanofi.com or + 353 1 403 5600.
Date of preparation March 2023